BioCryst Pharmaceuticals Inc. (BCRX)
Summary
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
BioCryst Pharmaceuticals NASDAQ: BCRX is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event.
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst's royalty financing obligations declined from $465.7 million at the end of Q4 2025 to $426.8 million at the end of June.
BioCryst Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 867 | $8,168.61 | $6,979.35 | -$1,189.26 | -14.56% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 66,855 | $668,550 | $538,182.75 | -$130,367.25 | -19.5% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 2 | $19 | $16.03 | -$2.97 | -15.63% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 52 | $549.1 | $418.6 | -$130.5 | -23.77% |
| NA Nizar Araji National Bank Of Canada /FI/ | 5,912 | $55,524 | $47,414.24 | -$8,109.76 | -14.61% |
BioCryst Pharmaceuticals Inc. (BCRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioCryst Pharmaceuticals Inc. ever had a stock split?
BioCryst Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Charles K. Gayer CEO | NASDAQ (NGS) Exchange | 09058V103 CUSIP |
| US Country | 435 Employees | - Last Dividend | - Last Split | 3 Mar 1994 IPO Date |
Overview
BioCryst Pharmaceuticals, Inc. is a pioneering biotechnology company focused on the development of oral small-molecule and protein therapeutics aimed at treating rare diseases. Established in 1986, the company is positioned at the forefront of medical research, utilizing cutting-edge technology and innovative approaches to create treatments that significantly improve patient outcomes. Headquartered in Durham, North Carolina, BioCryst maintains a global presence through strategic collaborations and in-license relationships with various internationally recognized institutions and companies. These partnerships enhance the firm's research capabilities and facilitate the broad distribution of its products, reinforcing its commitment to addressing unmet medical needs worldwide.
Products and Services
- Peramivir Injection (RAPIVAB, RAPIACTA, PERAMIFLU)
This product is an intravenous neuraminidase inhibitor designed for the treatment of acute uncomplicated influenza. By targeting the neuraminidase enzyme, peramivir prevents the release of new virus particles, effectively limiting the spread of the influenza virus within the body. Its intravenous administration ensures rapid delivery and action, offering a significant benefit for patients requiring immediate treatment.
- ORLADEYO (Oral Serine Protease Inhibitor)
ORLADEYO is an innovative treatment for hereditary angioedema, a rare and potentially life-threatening genetic condition. As an oral serine protease inhibitor, ORLADEYO works by inhibiting the activity of specific enzymes involved in the cascade of events that lead to angioedema attacks. This treatment represents a significant advancement in the management of hereditary angioedema, providing patients with a convenient oral medication option.
- BCX10013 (Oral Factor D Inhibitor)
Currently under development, BCX10013 is an oral factor D inhibitor targeting complement-mediated diseases. Factor D is a crucial enzyme in the complement pathway, a part of the immune system that plays a key role in inflammation and cell destruction. By inhibiting factor D, BCX10013 aims to provide a novel treatment option for patients with complement-mediated conditions, showcasing BioCryst's commitment to expanding its portfolio of innovative therapies.
Contact Information
